Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Key Points
MAIN FINDING: The combination of tifcemalimab and toripalimab shows potential effectiveness in treating advanced lung cancer.
KEY EVIDENCE: Immunohistochemistry results illustrate the impact of the treatment on lymphocyte activity in cancer tissues.
APPROACH: The study utilized phase I/II clinical trial data assessing the combination of two antibodies.
SIGNIFICANCE: This research may lead to new strategies in managing advanced lung cancer for previously treated patients.
Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer | Synapse